All Q2 FY26 results →

GB

Godavari Bioref.

Q2 FY26Diversified FMCG

Godavari Bioref. Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹244

Market cap₹1.3K Cr

P/E43.6

Updated23 Aug 2026

Read4 min read

The short version

Godavari Biorefineries expects overall revenue and EBITDA growth over the next 2-3 years, driven by multiple business segments. Godavari Biorefineries expects revenue and EBITDA growth over the next 2-3 years driven by: - Expansion in high-value bio-based specialty chemicals.

From Godavari Bioref.'s Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Godavari Biorefineries expects overall revenue and EBITDA growth over the next 2-3 years, driven by multiple business segments.
Expansion of ethanol business through multi-feedstock capacity including the commissioning of a 200 KLPD grain-based ethanol plant in Q4 FY26.
Growth in bio-based specialty chemicals, aiming to increase their share within the chemical business, which has already contributed to improved profitability.
Scaling branded Jivana products (such as sugar, brown sugar, jaggery, turmeric) to strengthen price resilience and market presence.
Continued investments in debottlenecking chemical plants and exploring new product additions.
Sales from new ethanol plant depend on OMC tenders; expected annual capacity around 60 million liters.

2 more points from Godavari Bioref.'s call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Godavari Biorefineries expects revenue and EBITDA growth over the next 2-3 years driven by:
Expansion in high-value bio-based specialty chemicals.
Increased multi-feedstock ethanol capacity including the upcoming grain-based ethanol facility (200 KLPD) commissioning in Q4 FY26.
Growth in branded consumer products under the Jivana brand.
Advances in drug discovery with potential out-licensing opportunities in 2-3 years.
Early signs of recovery in Q2 FY26 with 34% YoY revenue growth and EBITDA losses narrowing significantly.
Ethanol segment returned to positive EBITDA in Q2 FY26.
Continuous focus on cost optimization, debottlenecking, and strategic investments to improve margins.

2 more points from Godavari Bioref.'s call on margins

Pro opens every point from 15K+ earnings calls

See what Godavari Bioref. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Commissioning of a 200 KLPD fungible grain-based ethanol distillery planned in Q4 FY 2026 to enhance ethanol production capacity and feedstock flexibility.
Ongoing engineering work and customer commitment assessments for a new biobutanol project; investment dependent on securing strong customer commitments.
Planned preliminary efficacy trials for anti-cancer molecules, with a US-facing subsidiary being set up to facilitate out-licensing; capital outlay details to be shared in the next quarter but expected to be modest relative to larger capex goals.

2 more points from Godavari Bioref.'s call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

There is no specific mention of any current or planned new fundraising through debt or equity in the provided transcript.
The company has focused on debt reduction as part of its strategy to improve cash flow and reinvest strategically.
Samir Somaiya mentioned planned capital expenditure of INR 325 crores by FY29 for core activities, but no clear indication that this will be funded by new fundraising.
For the anti-cancer molecule project, the expected capital outlay over the next 2-3 years is stated to be not substantial enough to affect larger capex goals.

2 more points from Godavari Bioref.'s call on fundraising

Pro opens every point from 15K+ earnings calls

See what Godavari Bioref. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Godavari Biorefineries Limited. However, relevant points related to future sales and tenders include: - Sales from the upcoming 200 KLPD grain-based ethanol plant in FY27 depend on tenders floated by Oil Marketing Companies (OMCs). - OMCs typically issue tenders annually, with the next expected around September 2026 for the latter half of FY27. - The plant capacity is about 60 million liters of ethanol per annum, with sales contingent on winning OMC tenders.

2 more points from Godavari Bioref.'s call on order book

Pro opens every point from 15K+ earnings calls

Godavari Bioref. — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024Q3 FY25

Mar 2025Q4 FY25

Jun 2025Q1 FY26

Sep 2025Q2 FY26

Dec 2025Q3 FY26

Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹564 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Godavari Bioref.'s management said in earlier quarters

Others in Diversified FMCG this season

ITC Ltd (Q2 FY26)
19,148 cr.; down 2.7% YoY (Page 39) . Key concall takeaways from ITC Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
Hindustan Foods Ltd (Q2 FY26)
Planned capex of INR550 crores through internal accruals and prudent debt, with Board approval for up to 1:1 debt-equity ratio. Key concall takeaways from…
Hind. Unilever (Q2 FY26)
EPS (Profit After Tax) grew 4% year-on-year despite a 4% decline in Profit After Tax before exceptional items, reflecting one-off tax benefits. Key concall…

Compare:vs Hind. Unilever vs ITC Ltd vs Hindustan Foods Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Godavari Bioref. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Godavari Bioref. Q2 FY26 results?

Godavari Biorefineries expects overall revenue and EBITDA growth over the next 2-3 years, driven by multiple business segments. Godavari Biorefineries expects revenue and EBITDA growth over the next 2-3 years driven by: - Expansion in high-value bio-based specialty chemicals.

What is Godavari Bioref. share price analysis?

Godavari Bioref. currently shows a neutral. The stock trades at a P/E of 43.6 with a market cap of ₹1,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Godavari Bioref. planning capital expenditure?

Commissioning of a 200 KLPD fungible grain-based ethanol distillery planned in Q4 FY 2026 to enhance ethanol production capacity and feedstock flexibility.

Keep Godavari Bioref. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.